449. Da Silva I. P., Ahmed T., Lo S., Reijers I. L. M., Weppler A., Warner A. B., Patrinely J. R., Serra-Bellver P., Lebbe C., Mangana J., Nguyen K., Zimmer L., Ascierto P. A., Stout D., Lyle M., Klein O., Gerard C. L., Blank C. U., Menzies A. M., Long G. V. Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy. // J Clin Oncol. ‒ 2020. ‒ T. 38.
450. Yi J. H., Yi S. Y., Lee H. R., Lee S. I., Lim D. H., Kim J. H., Park K. W., Lee J. Dacarbazine-based chemotherapy as first-line treatment in noncutaneous metastatic melanoma: multicenter, retrospective analysis in Asia // Melanoma Res. ‒ 2011. ‒ T. 21, № 3. ‒ C. 223-7.
451. Serrone L., Zeuli M., Sega F. M., Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview // J Exp Clin Cancer Res. ‒ 2000. ‒ T. 19, № 1. ‒ C. 21-34.
452. Hill G. J., 2nd, Krementz E. T., Hill H. Z. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A) // Cancer. ‒ 1984. ‒ T. 53, № 6. ‒ C. 1299-305.
453. Middleton M. R., Grob J. J., Aaronson N., Fierlbeck G., Tilgen W., Seiter S., Gore M., Aamdal S., Cebon J., Coates A., Dreno B., Henz M., Schadendorf D., Kapp A., Weiss J., Fraass U., Statkevich P., Muller M., Thatcher N. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma // J Clin Oncol. ‒ 2000. ‒ T. 18, № 1. ‒ C. 158-66.
454. МАНЗЮК Л., БОРОДКИНА А., АРТАМОНОВА Е., НАДЕЖДИНА Т., ТОКАРЕВА З., ХАЛЯСТОВ И. Опыт применения лекарственных комбинаций на основе аранозы при лечении диссеминированной меланомы кожи // Вестник РОНЦ им. Н. Н. Блохина РАМН. ‒ 2000. ‒ T. 11, № 2. ‒ C. 4.
455. Hauschild A., Agarwala S. S., Trefzer U., Hogg D., Robert C., Hersey P., Eggermont A., Grabbe S., Gonzalez R., Gille J., Peschel C., Schadendorf D., Garbe C., O'Day S., Daud A., White J. M., Xia C., Patel K., Kirkwood J. M., Keilholz U. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma // J Clin Oncol. ‒ 2009. ‒ T. 27, № 17. ‒ C. 2823-30.
456. Samoylenko I., Kharkevich G., Petenko N. N., Orlova K., Sinelnikov I., Utyashev I., Vikhrova A., Markina I., Demidov L. Paclitaxel and carboplatin chemotherapy in patients with metaststic melanoma refractory to BRAF/MEK inhibitors // J Clin Oncol. ‒ 2016. ‒ T. 34. ‒ C. No 15_suppl (May 20 Supplement), 2016: 9552.
457. Ives N. J., Stowe R. L., Lorigan P., Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients // J Clin Oncol. ‒ 2007. ‒ T. 25, № 34. ‒ C. 5426-34.
458. Atkins M. B., Hsu J., Lee S., Cohen G. I., Flaherty L. E., Sosman J. A., Sondak V. K., Kirkwood J. M., Eastern Cooperative Oncology G. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group // J Clin Oncol. ‒ 2008. ‒ T. 26, № 35. ‒ C. 5748-54.
459. Carbone P. P., Costello W. Eastern Cooperative Oncology Group studies with DTIC (NSC-45388) // Cancer Treat Rep. ‒ 1976. ‒ T. 60, № 2. ‒ C. 193-8.
460. Nashan D., Muller M. L., Grabbe S., Wustlich S., Enk A. Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine // J Eur Acad Dermatol Venereol. ‒ 2007. ‒ T. 21, № 10. ‒ C. 1305-18.
461. Diez B. D., Statkevich P., Zhu Y., Abutarif M. A., Xuan F., Kantesaria B., Cutler D., Cantillon M., Schwarz M., Pallotta M. G., Ottaviano F. H. Evaluation of the exposure equivalence of oral versus intravenous temozolomide // Cancer Chemother Pharmacol. ‒ 2010. ‒ T. 65, № 4. ‒ C. 727-34.
462. Larkin J. M., Hughes S. A., Beirne D. A., Patel P. M., Gibbens I. M., Bate S. C., Thomas K., Eisen T. G., Gore M. E. A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma // Br J Cancer. ‒ 2007. ‒ T. 96, № 1. ‒ C. 44-8.
463. Ahmann D. L., Hahn R. G., Bisel H. F. A Comparative Study of 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037) and Imidazole Carboxamide (NSC 45388) with Vincristine (NSC 67574) in the Palliation of Disseminated Malignant Melanoma // Cancer Research. ‒ 1972. ‒ T. 32, № 11. ‒ C. 2432-2434.
464. Hill G. J., 2nd, Ruess R., Berris R., Philpott G. W., Parkin P. Chemotherapy of malignant melanoma with dimethyl traizeno imidazole carboxamide (DITC) and nitrosourea derivatives (BCNU, CCNU) // Ann Surg. ‒ 1974. ‒ T. 180, № 2. ‒ C. 167-74.
465. Eton O., Legha S. S., Bedikian A. Y., Lee J. J., Buzaid A. C., Hodges C., Ring S. E., Papadopoulos N. E., Plager C., East M. J., Zhan F., Benjamin R. S. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial // J Clin Oncol. ‒ 2002. ‒ T. 20, № 8. ‒ C. 2045-52.
466. Samoylenko I. V., Zabotina T. N., Mikhaylova I. N., Chkadua G. Z., Korotkova O. V., Baryshnikov K., Demidov L. V. 1138P - Chemotherpay and Dendritic Cell Vaccine in Patient with Metastatic Melanoma: Phase II Prospective Randomized Trial // Annals of Oncology. ‒ 2012. ‒ T. 23. ‒ C. ix371.
467. Flaherty K. T., Lee S. J., Zhao F., Schuchter L. M., Flaherty L., Kefford R., Atkins M. B., Leming P., Kirkwood J. M. Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma // Journal of Clinical Oncology. ‒ 2013. ‒ T. 31, № 3. ‒ C. 373-379.